OPEN END TURBO OHNE STOP-LOSS - VIVORYON THERAPEUTICS

OPEN END TURBO OHNE STOP-LOSS - VIVORYON THERAPEUTICS Stock

DE000LX39G98

Market Closed - Börse Stuttgart 02:12:52 2024-07-12 am EDT
1.45 ^EUR	+3.57%

Current month	-1.41%
1 month	-20.45%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VIVORYON THERAPEUTICS N.V.

Chart OPEN END TURBO OHNE STOP-LOSS - VIVORYON THERAPEUTICS

Latest news about VIVORYON THERAPEUTICS N.V.

Vivoryon Therapeutics N : Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease	Jul. 09	PU
Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease	Jul. 09	GL
Vivoryon Therapeutics N.V.(ENXTAM:VVY) dropped from Netherlands ASCX AMS Small Cap Index	Jun. 23	CI
Vivoryon Therapeutics N.V.(ENXTAM:VVY) dropped from S&P Global BMI Index	Jun. 23	CI

More news

Quotes 5-day view

Date	Price	Change
24-07-12	1.45	+3.57%
24-07-11	1.4	+17.65%
24-07-10	1.19	0.00%
24-07-09	1.19	0.00%
24-07-08	1.19	-4.03%

Delayed Quote Börse Stuttgart

Last update July 12, 2024 at 02:12 am EDT

More quotes

Static data

Product type	Knock-Out without Stop Loss
Buy / Sell	CALL
Underlying	VIVORYON THERAPEUTICS N.V.
Issuer	Lang & Schwarz
WKN	LX39G9
ISIN	DE000LX39G98
Date issued	2024-06-05
Strike	1.057 €
Maturity	Unlimited
Parity	1 : 1
Emission price	1.85 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	2.34 €
Lowest since issue	0.84 €

Company Profile

Vivoryon Therapeutics N.V. specializes in the research and development of therapeutic products for the treatment of Alzheimer disease. At the end of 2023, the group has a portfolio of a product in phase II-B clinical development (Varoglutamstat; PQ912).

Sector

More about the company

Consensus: Vivoryon Therapeutics N.V.

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.18 EUR

Average target price

30.35 EUR

Spread / Average Target

+1,292.20%

Consensus